Đang chuẩn bị liên kết để tải về tài liệu:
The clinical response to vemurafenib in a patient with a rare BRAFV600DK601 del mutation-positive melanoma
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Mutations in the activation segment of the v-raf murine sarcoma viral oncogene homolog B (BRAF) gene are present in approximately 50% of melanomas. The selective BRAF inhibitor vemurafenib has demonstrated significant clinical benefits in patients with melanomas harboring the most common mutations (V600E, V600K and V600R). |